---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Diagnosis"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Diagnosis. Topics: Cystoscopy and histological confirmation, Urine cytology, Transurethral resection and bladder and prostatic urethral biopsies, Imaging and evaluation of the upper urinary tract, and 4 further topics. 8 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/diagnosis"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Cystoscopy and histological confirmation

> “The diagnosis of papillary BC ultimately depends on cystoscopic examination of the bladder and histological evaluation of sampled tissue by either cold-cup biopsy or resection.”
> “Carcinoma in situ can be suspected based on cystoscopy and urine cytology and confirmed by histological evaluation of multiple bladder biopsies”
> “Perform cystoscopy with or without biopsy confirmation in patients with symptoms suggestive of BC. It cannot be replaced by cytology or by any other non-invasive test.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “When bladder cancer is suspected, the most useful diagnostic test is cystoscopy.”
> “Radiological studies such as CT scans or ultrasound do not have sufficient sensitivity to detect bladder cancers.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

<a id="topic-2.2.1.5-2"></a>

### Urine cytology

> “The examination of voided urine or bladder-washing specimens for exfoliated cancer cells has high sensitivity in HG/G3 tumours (84%), but low sensitivity in LG/G1 tumours (16%)”
> “The sensitivity in CIS detection is 28-100%”
> “Positive voided urinary cytology can indicate an UC anywhere in the urinary tract; however, negative cytology does not exclude its presence.”
> “Use voided urine cytology as an adjunct to cystoscopy to detect high-grade tumour.”
> “Use the Paris System 2nd Edn., for cytology reporting.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.5-3"></a>

### Transurethral resection and bladder and prostatic urethral biopsies

> “Perform a transurethral resection of the bladder tumour (TURBT) followed by pathology investigation of the obtained specimen(s) as a diagnostic procedure and initial treatment step in patients suspected of having bladder cancer (BC).”
> “The absence of detrusor muscle in the specimen is associated with a significantly higher risk of residual disease and tumour under-staging (with the exception of Ta LG/G1 tumours).”
> “In patients with positive cytology but negative cystoscopy, exclude an upper tract urothelial carcinoma, CIS in the bladder (by mapping biopsies or PDD-guided biopsies) and tumour in the prostatic urethra (by prostatic urethra biopsy).”
> “Photodynamic diagnosis has been shown to improve the detection of BC, especially CIS.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.5-4"></a>

### Imaging and evaluation of the upper urinary tract

> “A diagnosis of CIS cannot be made using imaging methods alone (CT urography, IVU, US), including mpMRI”
> “Once a bladder tumour has been detected, perform a CT urography in selected cases (e.g. tumours located in the trigone, or multiple- or high-risk tumours).”
> “Voided urine cytology, cystoscopy and CT urography are key investigations for early detection of extravesical recurrence.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “If a high-grade cancer (including carcinoma in situ) or invasive cancer is seen, the patient is staged with a CT scan of the abdomen and pelvis (or CT urogram) and either a chest x-ray or chest CT scan.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

<a id="topic-2.2.1.5-5"></a>

### Urinary molecular markers after BCG

> “Benign conditions and previous Bacillus Calmette-Guérin (BCG) instillations may influence the results of many urinary marker tests”
> “none of these markers have been accepted in routine practice by any clinical guidelines for diagnosis”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.5-6"></a>

### Detection of recurrence during follow-up of high-risk disease

> “The first cystoscopy after TURBT at three months is an important prognostic indicator for recurrence and progression”
> “Therefore, the best surveillance strategy for these patients will continue to include frequent cystoscopy and voided urine cytology.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.5-7"></a>

### Establishing BCG-unresponsive status: documentation of prior BCG

> “Type of BCG schedule administered before failure (including induction and maintenance: instillations per course, schedule of instillations and duration)”
> “The timing of recurrence and type of BCG schedule administered before failure should also be documented.”

Source: [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)

> “If a patient has met criteria for”
> “BCG-unresponsive disease at any time during their treatment course, sponsors can consider that”
> “patient to have BCG-unresponsive NMIBC regardless of whether BCG was the most recent”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-2.2.1.5-8"></a>

### Characterization of disease extent in BCG-unresponsive trials

> “Investigators should fully characterize a”
> “patient’s disease status at or before trial entry, for example through mandatory templated”
> “biopsies in patients with CIS. Sponsors should also obtain urine cytology.”
> “base of the lesion (the biopsy should contain muscle fibers) before trial entry to ensure the”
> “Sponsors should use imaging by”
> “computerized tomography or magnetic resonance to further evaluate patients for the presence of”
> “The 2004 World Health Organization/International Society of”
> “Urologic Pathology classification system is the preferred system for tumor grading.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
